Literature DB >> 9487255

Medically certified work loss, recurrence and costs of wage compensation for back pain: a follow-up study of the working population of Jersey.

P J Watson1, C J Main, G Waddell, T F Gales, G Purcell-Jones.   

Abstract

The 1 yr incidence, prevalence and wages compensation costs of work loss due to medically certified back pain in the working population of Jersey were identified by analysis of the Social Security database for the year 1994. A total of 2291 subjects absenting due to back pain during this period were followed for up to 3 yr to identify return to work rates and subsequent absences. Incidence and prevalence rates were 5.6 and 6.3%, respectively. The cost of wages compensation was 1.29 million pounds or 10.5% of such benefits paid. Work loss was greater for the second absence. The rate of return to work was broadly in line with that suggested by the Clinical Standards Advisory Group (CSAG), but the number still absent at 1 yr was less, suggesting that the CSAG figures for long-term absence may have been overestimated. The influence of compensation systems and unemployment on work-related absence due to back pain is highlighted.

Entities:  

Mesh:

Year:  1998        PMID: 9487255     DOI: 10.1093/rheumatology/37.1.82

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  16 in total

Review 1.  Methodological challenges in studying recurrence of low back pain.

Authors:  Radoslaw Wasiak; Glenn S Pransky; Barbara S Webster
Journal:  J Occup Rehabil       Date:  2003-03

2.  Routine primary care management of acute low back pain: adherence to clinical guidelines.

Authors:  Violeta González-Urzelai; Loreto Palacio-Elua; Josefina López-de-Munain
Journal:  Eur Spine J       Date:  2003-11-06       Impact factor: 3.134

Review 3.  Physical exercise interventions to improve disability and return to work in low back pain: current insights and opportunities for improvement.

Authors:  J Bart Staal; James Rainville; Julie Fritz; Willem van Mechelen; Glenn Pransky
Journal:  J Occup Rehabil       Date:  2005-12

4.  Evidence-based gallbladder cancer staging: changing cancer staging by analysis of data from the National Cancer Database.

Authors:  Yuman Fong; Lawrence Wagman; Mithat Gonen; James Crawford; William Reed; Richard Swanson; Charlie Pan; Jamie Ritchey; Andrew Stewart; Michael Choti
Journal:  Ann Surg       Date:  2006-06       Impact factor: 12.969

5.  Predicting the long term course of low back pain and its consequences for sickness absence and associated work disability.

Authors:  A Burdorf; J P Jansen
Journal:  Occup Environ Med       Date:  2006-08       Impact factor: 4.402

6.  Recurrence of medically certified sickness absence according to diagnosis: a sickness absence register study.

Authors:  C A M Roelen; P C Koopmans; J R Anema; A J van der Beek
Journal:  J Occup Rehabil       Date:  2010-03

7.  Design of a trial-based economic evaluation on the cost-effectiveness of employability interventions among work disabled employees or employees at risk of work disability: the CASE-study.

Authors:  Cindy Y G Noben; Frans J N Nijhuis; Angelique E de Rijk; Silvia M A A Evers
Journal:  BMC Public Health       Date:  2012-01-18       Impact factor: 3.295

8.  The epidemiology of low back pain in primary care.

Authors:  Peter M Kent; Jennifer L Keating
Journal:  Chiropr Osteopat       Date:  2005-07-26

9.  Structured early consultation with the occupational physician reduces sickness absence among office workers at high risk for long-term sickness absence: a randomized controlled trial.

Authors:  Ijmert Kant; Nicole W H Jansen; Ludovic G P M van Amelsvoort; Rudy van Leusden; Ate Berkouwer
Journal:  J Occup Rehabil       Date:  2008-01-15

Review 10.  Absence from work and return to work in people with back pain: a systematic review and meta-analysis.

Authors:  Gwenllian Wynne-Jones; Jemma Cowen; Joanne L Jordan; Olalekan Uthman; Chris J Main; Nick Glozier; Danielle van der Windt
Journal:  Occup Environ Med       Date:  2013-11-01       Impact factor: 4.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.